Fennec Pharmaceuticals Inc. (FENC)
FENCNASDAQ-CMBiotechnology: Biological Products (No Diagnostic Substances)
$10.64
0.0000 (0.00%) today
Pre-market, Nov 11, 4:00 PM ET
- Market cap
- $372.76m
- P/E
- –
- EPS, last 4 quarters
- $-0.0700
- Dividend yield
- –
- Day range
- –
- 52-week range
- $5.65 to $13.25
- Average volume
- –
- Previous close
- $10.64
Analysts
3 coveringBuy3 buy, 0 hold, 0 sell
Targets a year out average $18.00, +69.2% from here
Earnings
next estimate $0.0900Next report
Sep 2025
+75.0%
Dec 2025
-466.7%
Mar 2026
+150.0%
Jun 2026
+400.0%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $12.46m | $13.78m | $15.11m | $17.87m |
| Gross profit | $11.80m | $12.01m | $14.54m | $17.15m |
| Operating income | -$188.0k | -$2.55m | -$119.0k | $1.74m |
| Net income | -$637.0k | -$4.79m | $201.0k | $1.97m |
Last four quarters: revenue $59.22m, margin -5.5%, free cash flow –
News
8 latest- C4 Therapeutics, Inc. (CCCC) Reports Q3 Loss, Lags Revenue EstimatesZacks · 7 days ago
- Fennec To Present Detailed Phase 2 Pedmark Data From STS-J01 Study At SIOP 2026 RTTNews · Sep 17, 2026
- Can Adherex Technologies (FENC) Climb 26.53% to Reach the Level Wall Street Analysts Expect?Zacks · Aug 12, 2026
- Adherex Technologies Q2 Earnings Call HighlightsMarketBeat · Aug 11, 2026
- Fennec Pharmaceuticals' Q2 Sales Surge 78%; Adjusted EBITDA Turns Positive RTTNews · Aug 11, 2026
- Adherex Technologies Inc. (FENC) Beats Q2 Earnings and Revenue EstimatesZacks · Aug 11, 2026
- Septerna, Inc. (SEPN) Reports Q2 Loss, Beats Revenue EstimatesZacks · Aug 10, 2026
- Biotech Stocks At 52-Week Highs - HALO +20% On Q2 Results, FENC, AVLN, AMLX, CHE RTTNews · Aug 10, 2026
The company
Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company committed to the fight against ototoxicity in cancer patients who receive cisplatin-based chemotherapy. Fennec is focused on the commercialization of PEDMARK to reduce the risk of platinum-induced ototoxicity in cancer patients. PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and United Kingdom (U.K.) approval in October 2023 under the brand name PEDMARQSI. In March 2024, Fennec entered into an exclusive licensing agreement under which Norgine Pharmaceuticals Ltd., a leading European specialist pharmaceutical company, will commercialize PEDMARQSI in Europe, U.K., Australia and New Zealand. PEDMARQSI is now commercially available in multiple countries. PEDMARK has received Orphan Drug Exclusivity in the U.S. and.; PEDMARQSI has received Pediatric Use Marketing Authorization in Europe, which includes eight years plus two years of data and market protection.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- fennecpharma.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.